search
Back to results

Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients

Primary Purpose

Postoperative Neurocognitive Disorders

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Intranasal insulin
Intranasal saline
Sponsored by
First Affiliated Hospital Xi'an Jiaotong University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Postoperative Neurocognitive Disorders focused on measuring postoperative neurocognitive disorders, Intranasal insulin

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients under general anesthesia through oral intubation; Patients undergoing elective extrathoracic, breast, orthopaedic, urological, abdominal and gynecological operations; Age ≥ 65 years; Cardiac function grade I~II (NYHA standard), ASA grade I~III; Volunteer for anticipating study and sign an informed consent form; Exclusion Criteria: Diabetes patients; Previous history of craniocerebral and spinal cord trauma, surgery, stroke, and inability to place electrodes on the head; History of nasal cavity stuffiness, epistaxis, rhinitis, and nasopharynx surgery; The operation position is prone and it is difficult to implement intranasal administration; Those who cannot cooperate with the assessment of the scale or have delirium before operation; Preoperative fasting blood glucose<4 mmol/L; Those who have participated in other clinical trials.

Sites / Locations

  • First Affiliated Hospital of Xian Jiaotong UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Intranasal insulin group

Saline group

Arm Description

Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation

Before anesthesia induction, give the equal volumes'saline nasal spray, once per hour, 20 IU each time, until the end of the operation

Outcomes

Primary Outcome Measures

Incidence of postoperative delirium
Whether or not postoperative delirium happens

Secondary Outcome Measures

Incidence of delayed neurocognitive recovery within 30 days after surgery
Whether or not delayed neurocognitive recovery happens
Incidence of neurocognitive disorders within 1 year after surgery
Whether or not neurocognitive disorders happens
The PND Incidence
Whether or not postoperative neurocognitive disorders happensevents after surgery
Intraoperative electroencephalogram parameters
The intraoperative parameters recorded by electroencephalogram, including BIS occurrence time, the duration with PSI less than 25, spectrum analysis, power spectrum analysis.
the level of Neurocognitive biomarkers
Neurocognitive biomarkers includes amyloid-beta protein and tau protein.
ApoE-ε4 susceptibility
Whether or not carry ApoE-ε4

Full Information

First Posted
November 6, 2022
Last Updated
November 6, 2022
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Collaborators
Tang-Du Hospital, Tongji Hospital, Second Hospital of Shanxi Medical University, LanZhou University, Sichuan Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, 521 Hospital of NORINCO Group
search

1. Study Identification

Unique Protocol Identification Number
NCT05613491
Brief Title
Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients
Official Title
Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients: a Multicenter, Randomized, Double-blind, Placebo-controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 7, 2022 (Actual)
Primary Completion Date
July 31, 2023 (Anticipated)
Study Completion Date
August 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Collaborators
Tang-Du Hospital, Tongji Hospital, Second Hospital of Shanxi Medical University, LanZhou University, Sichuan Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, 521 Hospital of NORINCO Group

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Postoperative neurocognitive disorders (PND) are common postoperative complication of central nervous system, leading to increased risk of the working ability loss after surgery, longer hospital stay, increased medical costs and increased surgical mortality. It is classified as perioperative neurocognitive disorders in mental disorders.Aging is an important demographic characteristic in China, and the elderly is also a population susceptible to PND. There is a lack of targeted prevention and control measures for PND. Central insulin resistance is an important mechanism of cognitive impairment in elderly patients, and exogenous supply of central insulin may be an important measure to improve PND. Compared with conventional subcutaneous and intravenous supply, intranasal insulin administration not only has little effect on blood glucose and insulin levels, but also enters the center through the blood-brain barrier easily and efficiently. Long-term use of intranasal insulin can improve the cognitive function of chronic diseases, but there is a lack of clinical studies on improving PND by intranasal insulin. This study will verify the effectiveness of intranasal insulin in the PND improvement of elderly patients.
Detailed Description
This study is intended to carry out a large sample, multicenter, double-blind, randomized, placebo, and controlled clinical study. Elderly non diabetes patients undergoing elective extrathoracic, breast, orthopedic, urinary, abdominal, and gynecological operations under general anesthesia are included. They are randomly divided into intranasal insulin group or saline group. Before anesthesia induction, they are given the first nasal spray, once per hour, 20 IU insulin or equal volume saline each time until the end of the operation. Follow up 1 day before operation, 1-7 days after operation, 30 days and 12 months respectively, and evaluate cognition with relevant scales. To verify that compared with the same volume of saline, intranasal insulin can reduce the incidence of postoperative delirium, the incidence of PND 1 year after surgery, and the related cognitive quantitative indicators of ApoE- ɛ4 Gene susceptibility, intraoperative EEG parameters, NfL, IL-6, IL-10, CRP and other biochemical indicators were used to explore the mechanism of intranasal insulin to improve PND.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Neurocognitive Disorders
Keywords
postoperative neurocognitive disorders, Intranasal insulin

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
438 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intranasal insulin group
Arm Type
Experimental
Arm Description
Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
Arm Title
Saline group
Arm Type
Placebo Comparator
Arm Description
Before anesthesia induction, give the equal volumes'saline nasal spray, once per hour, 20 IU each time, until the end of the operation
Intervention Type
Drug
Intervention Name(s)
Intranasal insulin
Other Intervention Name(s)
Insulin injection,H10890001,Jiangsu Wanbang Biochemical Medicine Group Co., Ltd
Intervention Description
Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
Intervention Type
Drug
Intervention Name(s)
Intranasal saline
Other Intervention Name(s)
0.9% sodium chloride,H20013250,Shanghai Baite Medical Supplies Co., Ltd
Intervention Description
Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
Primary Outcome Measure Information:
Title
Incidence of postoperative delirium
Description
Whether or not postoperative delirium happens
Time Frame
0-7 days after surgery
Secondary Outcome Measure Information:
Title
Incidence of delayed neurocognitive recovery within 30 days after surgery
Description
Whether or not delayed neurocognitive recovery happens
Time Frame
0-30 days after surgery
Title
Incidence of neurocognitive disorders within 1 year after surgery
Description
Whether or not neurocognitive disorders happens
Time Frame
30 day-1 year after surgery
Title
The PND Incidence
Description
Whether or not postoperative neurocognitive disorders happensevents after surgery
Time Frame
0 day-1 year after surgery
Title
Intraoperative electroencephalogram parameters
Description
The intraoperative parameters recorded by electroencephalogram, including BIS occurrence time, the duration with PSI less than 25, spectrum analysis, power spectrum analysis.
Time Frame
Surgery day
Title
the level of Neurocognitive biomarkers
Description
Neurocognitive biomarkers includes amyloid-beta protein and tau protein.
Time Frame
0 day-1 year after surgery
Title
ApoE-ε4 susceptibility
Description
Whether or not carry ApoE-ε4
Time Frame
1 day before surgery

10. Eligibility

Sex
All
Gender Based
Yes
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients under general anesthesia through oral intubation; Patients undergoing elective extrathoracic, breast, orthopaedic, urological, abdominal and gynecological operations; Age ≥ 65 years; Cardiac function grade I~II (NYHA standard), ASA grade I~III; Volunteer for anticipating study and sign an informed consent form; Exclusion Criteria: Diabetes patients; Previous history of craniocerebral and spinal cord trauma, surgery, stroke, and inability to place electrodes on the head; History of nasal cavity stuffiness, epistaxis, rhinitis, and nasopharynx surgery; The operation position is prone and it is difficult to implement intranasal administration; Those who cannot cooperate with the assessment of the scale or have delirium before operation; Preoperative fasting blood glucose<4 mmol/L; Those who have participated in other clinical trials.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Qiang Wang, MD,PHD
Phone
0086-18049286968
Email
dr.wangqiang@139.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Qiang Wang, MD,PHD
Organizational Affiliation
First Affiliated Hospital of Xian JiaotongUniversity
Official's Role
Study Chair
Facility Information:
Facility Name
First Affiliated Hospital of Xian Jiaotong University
City
Xi'an
State/Province
Shannxi
ZIP/Postal Code
029710061
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qiang Wang, MD,PHD
Phone
0086-18049286968
Email
dr.wangqiang@163.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The research plan will not be made public until the research results are published
Citations:
PubMed Identifier
30336844
Citation
Evered L, Silbert B, Knopman DS, Scott DA, DeKosky ST, Rasmussen LS, Oh ES, Crosby G, Berger M, Eckenhoff RG; Nomenclature Consensus Working Group. Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery-2018. Br J Anaesth. 2018 Nov;121(5):1005-1012. doi: 10.1016/j.bja.2017.11.087. Epub 2018 Jun 15.
Results Reference
background
PubMed Identifier
29133765
Citation
Liu Y, Xiao W, Meng LZ, Wang TL. Geriatric Anesthesia-related Morbidity and Mortality in China: Current Status and Trend. Chin Med J (Engl). 2017 Nov 20;130(22):2738-2749. doi: 10.4103/0366-6999.218006.
Results Reference
background
PubMed Identifier
21474666
Citation
Evered L, Scott DA, Silbert B, Maruff P. Postoperative cognitive dysfunction is independent of type of surgery and anesthetic. Anesth Analg. 2011 May;112(5):1179-85. doi: 10.1213/ANE.0b013e318215217e. Epub 2011 Apr 7.
Results Reference
background
PubMed Identifier
32210695
Citation
Jayaraj RL, Azimullah S, Beiram R. Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators. Saudi J Biol Sci. 2020 Feb;27(2):736-750. doi: 10.1016/j.sjbs.2019.12.028. Epub 2019 Dec 26.
Results Reference
background
PubMed Identifier
30381076
Citation
Li X, Run X, Wei Z, Zeng K, Liang Z, Huang F, Ke D, Wang Q, Wang JZ, Liu R, Zhang B, Wang X. Intranasal Insulin Prevents Anesthesia-induced Cognitive Impairments in Aged Mice. Curr Alzheimer Res. 2019;16(1):8-18. doi: 10.2174/1567205015666181031145045.
Results Reference
background
PubMed Identifier
28539885
Citation
Chen Y, Dai CL, Wu Z, Iqbal K, Liu F, Zhang B, Gong CX. Intranasal Insulin Prevents Anesthesia-Induced Cognitive Impairment and Chronic Neurobehavioral Changes. Front Aging Neurosci. 2017 May 10;9:136. doi: 10.3389/fnagi.2017.00136. eCollection 2017.
Results Reference
background
PubMed Identifier
26879001
Citation
Zhang Y, Dai CL, Chen Y, Iqbal K, Liu F, Gong CX. Intranasal Insulin Prevents Anesthesia-Induced Spatial Learning and Memory Deficit in Mice. Sci Rep. 2016 Feb 16;6:21186. doi: 10.1038/srep21186.
Results Reference
background
PubMed Identifier
25374101
Citation
Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis. 2015;44(3):897-906. doi: 10.3233/JAD-141791. Erratum In: J Alzheimers Dis. 2015;45(4):1269-70.
Results Reference
background
PubMed Identifier
17643054
Citation
Benedict C, Hallschmid M, Schultes B, Born J, Kern W. Intranasal insulin to improve memory function in humans. Neuroendocrinology. 2007;86(2):136-42. doi: 10.1159/000106378. Epub 2007 Jul 20.
Results Reference
background
PubMed Identifier
29180222
Citation
Chapman CD, Schioth HB, Grillo CA, Benedict C. Intranasal insulin in Alzheimer's disease: Food for thought. Neuropharmacology. 2018 Jul 1;136(Pt B):196-201. doi: 10.1016/j.neuropharm.2017.11.037. Epub 2017 Nov 24.
Results Reference
background
PubMed Identifier
15288712
Citation
Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004 Nov;29(10):1326-34. doi: 10.1016/j.psyneuen.2004.04.003.
Results Reference
background
PubMed Identifier
24101698
Citation
Novak V, Milberg W, Hao Y, Munshi M, Novak P, Galica A, Manor B, Roberson P, Craft S, Abduljalil A. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care. 2014;37(3):751-9. doi: 10.2337/dc13-1672. Epub 2013 Oct 7.
Results Reference
background
PubMed Identifier
25337926
Citation
Brunner YF, Kofoet A, Benedict C, Freiherr J. Central insulin administration improves odor-cued reactivation of spatial memory in young men. J Clin Endocrinol Metab. 2015 Jan;100(1):212-9. doi: 10.1210/jc.2014-3018. Erratum In: J Clin Endocrinol Metab. 2016 Oct;101(10 ):3863.
Results Reference
background

Learn more about this trial

Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients

We'll reach out to this number within 24 hrs